



Delivering Care with Compassion and Expertise

At Bioclinica, we have worked for decades with patients at every stage of Alzheimer's disease and cognitive impairment. Our personnel understand the care and management necessary to keep such patients engaged with a clinical trial. Our facilities have been designed with the size and infrastructure required to conduct large prescreening programs and to execute the protocols of prodromal Alzheimer's disease/mild cognitive impairment clinical trials.

After two decades of intense – but unsuccessful – research into reversing moderate to severe cases of Alzheimer's disease (AD), the clinical trial paradigm is shifting. The hope now is for early intervention to prevent disease progression; however, that requires access to an entirely different patient population, composed of people who have prodromal AD or mild cognitive impairment (MCI) but are largely asymptomatic. The good news is that Bioclinica can locate these patients – and has the experience and infrastructure to care for them throughout the course of a clinical trial.

Finding Prodromal AD/MCI Patients

The challenge for the new clinical trial paradigm is that many people with prodromal AD/MCI are asymptomatic and not aware that their memory problems hold any significance. They are often not under the care of a geriatrician, psychiatrist, or neurologist. At best, they are asking their primary care physicians for advice. So how can such patients be identified for an AD clinical trial?

Bioclinica can meet this challenge – and rise above it. Our Research Network has conducted long-term studies for different indications (e.g., osteoporosis) that have included this precise patient population. As a result, we have an extensive database of patients who have varying degrees of AD/MCI. Our database also includes people over 50 who have expressed interest in memory research.

Candidate Database Breakdown*

Country	No. of Candidates	Country	No. of Candidates
Argentina	5,855	Estonia	18,750
Brazil	24,894	Hong Kong	19,494
Chile	3,800	Lithuania	35,662
China	24,760	Peru	3,875
Colombia	19,209	Poland	32,257
Czech Republic	29,468	Romania	11,361
Denmark	160,866	Grand Total	390,887

*as of May 2016



At Bioclinica, our entire infrastructure is designed with **CARE, EFFICIENCY, and COST-SAVINGS** in mind.



Patient-Centric Environment

Patients with AD/MCI often have to spend several hours at a facility while tests are conducted. Usually, they do not come alone – they have Study Partners who accompany them to the site. We have rooms specially designed for patients and their Study Partners where they can wait in comfort with computers, Internet access, TVs, music, and other conveniences.



Expert Raters

We have invested extensively in the education of our raters by partnering with a leading provider of rater training. Each of our sites has four to five trained raters who meet international quality standards. As with all our staff, our raters remain with us for the long-term. With no significant turnover, the same personnel provide consistent care for patients throughout the course of your study.



Specialized Resources

All our AD/MCI sites have access to:

- > Expert Raters
- > CT, MRI and PET Scans
- > Specialists
- > Lumbar Puncture



Targeted Technology

Our patented technologies can identify, screen, randomize, and process the large volumes of patients necessary for prodromal AD/MCI clinical studies.



Quality Data

Because we are able to randomize more patients at fewer sites, the variance of the data is lowered and overall quality of data improves. Additionally, the quantity of data for the study is increased through excellent patient engagement and retention.



Make a Successful Shift to a New AD/MCI Paradigm

Drug companies around the world are seeking to adjust to the new AD/MCI clinical trial paradigm. You can make the transition easier by partnering with Bioclinica. Our experience, recruitment capabilities, technology, and infrastructure are fully aligned with this new paradigm. We can help you find the volume of qualified patients you need for your prodromal AD/MCI clinical study, and provide the expert medical knowledge and patient care necessary to make your study a success.